A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

Incyte has reported positive top line data from the pivotal Phase III frontMIND trial assessing the safety and efficacy of ...

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for ...

As the world observes World Lymphoma Awareness Day on September 15th, it 39;s a timely reminder of the ongoing battle against ...

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

The FDA issued a complete response letter for glofitamab-gxbm plus gemcitabine and oxaliplatin (GemOx) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), citing insufficient STARGLO trial ...

Reply to: Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights Mosun-Pola demonstrated superior efficacy versus R-GemOx, with significant improvements ...

The top 5 most-viewed videos of 2025 explored a range of topics, including data presented at major medical meetings, health ...